로딩 중…
지수 로딩 중…
Evolus, Inc.
EOLS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$7.86-1.87%
2026-09-18
Financials
Valuation Metrics
Evolus, Inc.'s Market Cap is $518M. At end of 2025 it was $429M. Ranked #2778 of 3,121 in US market (top 89%), #1212 of 1,463 on NASDAQ (top 83%), #225 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $518M | US#2,778/3,121 Sec#225/266 |
| Revenue | $316M | US#2,440/3,121 Sec#93/266 |
| Net Income | $-34M | US—/3,121 Sec—/266 |
| Total Assets | $248M | US#2,961/3,121 Sec#232/266 |
| Net Assets | $-31M | US#2,944/3,121 Sec#247/266 |
| Employees | 350 | US#2,386/3,121 Sec#106/266 |
| Value | ||
| P/S | 1.64x | US#1,125/3,121 Sec#18/266 |
| FCF Yield | -3.90% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -13.84% | US#2,727/3,121 Sec#113/266 |
| Op. Margin | -7.33% | US#2,523/3,121 Sec#93/266 |
| Revenue Growth | 13.87% | US#984/3,121 Sec#85/266 |
| Financial Health | ||
| Total Debt | $165M | US#2,312/3,121 Sec#101/266 |
| FCF | $-20M | US#2,425/3,121 Sec#95/266 |
| Cash | $45M | US#2,617/3,121 Sec#233/266 |
| Current Ratio | 1.70x | US#1,474/3,121 Sec#234/266 |
| Performance | ||
| 1Y Return | 22.43% | US#1,088/3,121 Sec#150/266 |
| 1M Return | -8.60% | US#1,230/3,121 Sec#113/266 |
| From 52W High | -15.57% | US#1,041/3,121 Sec#72/266 |
| 1Y MDD | -46.54% | US#2,308/3,121 Sec#167/266 |
| Trading | ||
| Volume | 1,021,441 shares | US#1,237/3,121 Sec#131/266 |
| Trading Value | $8M | US#2,372/3,121 Sec#195/266 |
| Per Share | ||
| EPS | $-0.52 | US—/3,121 Sec—/266 |
| BPS | $-0.47 | US—/3,121 Sec—/266 |
Company Info
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.